January 8, 2014—U.S. hospitals provided a record-high $45.9 billion in unreimbursed care to indigent and underinsured patients in 2012, an 11.7 percent increase over 2011, according to a new American Hospital Association (AHA) report. … [Read more...]
PhRMA: Strike 340B Data in Orphan Drug Case
PhRMA has asked a federal judge to strike a hospital survey from a friend-of-the court brief filed by 340B healthcare providers. … [Read more...]
Hospitals Provided $45.9 Billion in Uncompensated Care in 2012
U.S. hospitals provided a record-high $45.9 billion in unreimbursed care to indigent and underinsured patients in 2012, an 11.7 percent increase over 2011, according to a new American Hospital Association (AHA) report. The uncompensated care total includes charity care and bad debt but excludes Medicaid and Medicare underpayment. 340B hospitals provide 62 percent of all … [Read more...]
Merck Announces 340B Refunds
Drugs Range from Remeron to FollistimPharmaceutical manufacturer Merck Sharp & Dohme Corp. has announced it will give refunds to 340B providers that bought certain products between 2002 and 2013. … [Read more...]
Hospitals Ask Court to Uphold Orphan Drug Rule
Support Broader Use Under 340BOrganizations representing safety-net healthcare providers filed a friend-of-the-court brief Dec. 20 supporting a Department Health and Human Services (HHS) rule that allows many of their members to receive discounted pricing on “orphan” drugs when not used to treat rare diseases. … [Read more...]
Limited Drug Coverage Under ACA Underscores Importance of 340B
Americans taking high-cost medications are finding that mid- to lower-tier health plans offered through the new insurance exchanges often don’t cover their prescriptions adequately. Many could end up underinsured, making the 340B program even more critical to keeping them healthy. Critics contend that insurance carriers are purposefully designing plans with weak pharmacy … [Read more...]
Orphan Drug Case Heats Up
Hospitals and other providers weighing in against PhRMAA flutter of briefs is landing at the U.S. District Court for the District of Columbia as hospitals square off against the pharmaceutical industry’s efforts to limit sales of discounted orphan drugs to 340B providers. … [Read more...]